Join Growin Stock Community!

Emergent biosolutions inc.EBS.US Overview

US StockHealthcare
(No presentation for EBS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EBS AI Insights

EBS Overall Performance

EBS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EBS Recent Performance

4.94%

Emergent biosolutions inc.

0.05%

Avg of Sector

-0.31%

S&P500

EBS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EBS Key Information

EBS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EBS Profile

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Price of EBS

EBS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EBS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.99
PE Ratio (TTM)
6.17
Forward PE
-
PS Ratio (TTM)
0.59
PB Ratio
1.00
Price-to-FCF
2.46
METRIC
VALUE
vs. INDUSTRY
Gross Margin
56.09%
Net Margin
7.08%
Revenue Growth (YoY)
-28.81%
Profit Growth (YoY)
15.02%
3-Year Revenue Growth
-23.39%
3-Year Profit Growth
-16.93%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.99
PE Ratio (TTM)
6.17
Forward PE
-
PS Ratio (TTM)
0.59
PB Ratio
1.00
Price-to-FCF
2.46
Gross Margin
56.09%
Net Margin
7.08%
Revenue Growth (YoY)
-28.81%
Profit Growth (YoY)
15.02%
3-Year Revenue Growth
-23.39%
3-Year Profit Growth
-16.93%

  • When is EBS's latest earnings report released?

    The most recent financial report for Emergent biosolutions inc. (EBS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EBS's short-term business performance and financial health. For the latest updates on EBS's earnings releases, visit this page regularly.

  • What is the operating profit of EBS?

    According to the latest financial report, Emergent biosolutions inc. (EBS) reported an Operating Profit of -27.9M with an Operating Margin of -18.76% this period, representing a decline of 193.68% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is EBS's revenue growth?

    In the latest financial report, Emergent biosolutions inc. (EBS) announced revenue of 148.7M, with a Year-Over-Year growth rate of -23.63%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does EBS have?

    At the end of the period, Emergent biosolutions inc. (EBS) held Total Cash and Cash Equivalents of 209.1M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does EBS go with three margins increasing?

    In the latest report, Emergent biosolutions inc. (EBS) did not achieve the “three margins increasing” benchmark, with a gross margin of 42.9%%, operating margin of -18.76%%, and net margin of -36.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EBS's profit trajectory and future growth potential.

  • Is EBS's EPS continuing to grow?

    According to the past four quarterly reports, Emergent biosolutions inc. (EBS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EBS?

    Emergent biosolutions inc. (EBS)'s Free Cash Flow (FCF) for the period is 73.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 190.77% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EBS?

    The latest valuation data shows Emergent biosolutions inc. (EBS) has a Price-To-Earnings (PE) ratio of 8.02 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.